格林巴利症候群 (GBS) 市場 - 按治療類型、類型、性別、年齡層、最終用戶 - 全球預測

在患者意識不斷增強的推動下，2024 年至 2032 年全球格林巴利症候群 (GBS) 市場複合年成長率將達到 4.6%。提高患者和倡導團體對格林巴利症候群 (GBS) 症狀、治療選擇和支持性護理的認知，在其管理中發揮關鍵作用。這種意識的提高可以更早識別症狀，促進及時的醫療干預並改善患者的治療結果。

根據美國國家神經疾病和中風研究所 (NINDS) 的報告，患者意識的提高和宣傳工作使格林-巴利綜合症的早期診斷和治療激增 20%，顯著改善了患者的治療結果和管理。

宣傳工作有助於增加 GBS 療法研究和支持服務的資金，從而改善整體患者護理。透過對患者和醫療保健提供者進行教育，倡導團體幫助確保受 GBS 影響的個人得到及時和適當的治療，從而有可能減少病情對患者生活影響的嚴重程度和持續時間。

整個吉蘭-巴利綜合症 (GBS) 市場根據治療類型、性別、類型、最終用戶、年齡層和地區進行分類。

到 2032 年，支持性治療領域將呈現強勁的複合年成長率。此外，醫療技術和治療方法的進步擴大了支持治療的範圍，為患者提供了更多緩解不適和促進復原的選擇。此外，隨著醫療保健系統強調整體患者護理，人們越來越重視在整個治療過程中提供全面支持，從而推動了針對 GBS 患者獨特需求的支持療法的需求。

到2032年，由於更好的診斷能力，慢性發炎性脫髓鞘多發性神經病變（CIDP）細分市場將獲得相當大的吉蘭-巴利症候群（GBS）市場佔有率，從而提高CIDP病例的識別率。 CIDP 和 GBS 治療方案的重疊（均涉及免疫調節療法）推動了該領域對專業護理的需求。此外，透過早期準確的診斷來改善患者的治療效果可以鼓勵積極主動的治療，從而刺激對標靶治療的需求。此外，神經學研究的醫療保健投資不斷增加，進一步促進了這些疾病有效治療方法的開發和可用性。

由於人口老化，更容易罹患自體免疫疾病，歐洲格林巴利症候群 (GBS) 市場從 2024 年到 2032 年將出現顯著的複合年成長率。此外，歐洲對醫療基礎設施和研究的投資增加也改善了獲得先進醫療保健和創新療法的機會。專注於早期診斷和全面患者護理的公共衛生措施推動了需求的不斷成長。歐洲神經病學協會提高認知活動和支持正在引導更多患者尋求及時有效的治療，從而提振了市場。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • GBS 發生率增加
    • 人們對罕見疾病治療的認知不斷增強
    • 政府扶持政策及資金
    • 擴大研發投入
    • 診斷和治療的進步
  • 產業陷阱與挑戰
    • 治療的不良反應
    • 監管和報銷挑戰
• 成長潛力分析
• 管道分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 一線治療
  • 靜脈注射免疫球蛋白 (IVIG)
  • 血漿交換（血漿去除術）
• 支持治療

第 6 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 急性發炎性脫髓鞘多發性神經病變（AIDP）
• 慢性發炎性脫髓鞘多發性神經根神經病變（CIDP）
• 米勒費雪症候群 (MFS)
• 急性運動軸突神經病變（AMAN）
• 其他類型

第 7 章：市場估計與預測：按性別分類，2021 - 2032 年

• 主要趨勢
• 男性
• 女性

第 8 章：市場估計與預測：按年齡分類，2021 - 2032

• 主要趨勢
• 20歲以下
• 21-40歲
• 41-59歲
• 60歲以上

第 9 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

• 主要趨勢
• 醫院
• 診所
• 復健中心
• 其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• AbbVie Inc.
• Biogen Inc.
• Cadila Healthcare Limited
• CSL Behring LLC
• F.Hoffmann-La Roche Ltd.
• GSK plc
• Grifols SA
• LGM Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Octapharma AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited

Global Guillain-Barre Syndrome (GBS) Market will record a 4.6% CAGR from 2024 to 2032, driven by growing patient awareness. Greater awareness among patients and advocacy groups about Guillain-Barre Syndrome (GBS) symptoms, treatment options, and supportive care plays a pivotal role in its management. This heightened awareness leads to earlier recognition of symptoms, facilitating prompt medical intervention and improving patient outcomes.

As per the National Institute of Neurological Disorders and Stroke (NINDS) report, better patient awareness and advocacy efforts have led to a 20% upsurge in early diagnosis and treatment of Guillain-Barre Syndrome, significantly improving patient outcomes and management.

Advocacy efforts contribute to increased funding for research into GBS therapies and support services, enhancing overall patient care. By educating both patients and healthcare providers, advocacy groups help ensure that individuals affected by GBS receive timely and appropriate treatment, thus potentially reducing the severity and duration of the condition's impact on patients' lives.

The overall Guillain-Barre syndrome (GBS) market is classified based on treatment type, gender, type, end-user, age group, and region.

The supportive treatments segment will exhibit a robust CAGR through 2032. As awareness of GBS increases, so does the recognition of the need for comprehensive supportive care to manage its symptoms effectively. Additionally, advancements in medical technology and therapeutic approaches have expanded the range of supportive treatments available, offering patients more options for alleviating discomfort and enhancing recovery. Moreover, with healthcare systems emphasizing holistic patient care, there is a growing emphasis on providing comprehensive support throughout the treatment journey, driving the demand for supportive therapies tailored to the unique needs of GBS patients.

The chronic inflammatory demyelinating polyneuropathy (CIDP) segment will garner a considerable Guillain-Barre syndrome (GBS) market share by 2032, owing to better diagnostic capabilities, leading to higher identification rates of CIDP cases. The overlap in treatment protocols for CIDP and GBS, both involving immune-modulating therapies, has driven the need for specialized care in this segment. Additionally, enhanced patient outcomes with early and accurate diagnosis encourage proactive management, spurring the demand for targeted therapies. Moreover, rising healthcare investments in neurological research further bolster the development and availability of effective treatments for these conditions.

Europe Guillain-Barre syndrome (GBS) market will register a noteworthy CAGR from 2024 to 2032, because of the aging population, which is more susceptible to autoimmune disorders. Additionally, increased investments in healthcare infrastructure and research in Europe have improved access to advanced medical care and innovative therapies. Public health initiatives focused on early diagnosis and comprehensive patient care contribute to the rising demand. Heightened awareness campaigns and support from European neurological associations are guiding more patients to seek timely and effective treatments, boosting the market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of GBS
    • 3.2.1.2 Growing awareness for rare disease treatment
    • 3.2.1.3 Government supporting policies and funding
    • 3.2.1.4 Expanding R&D investment
    • 3.2.1.5 Advancements in diagnostics and treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects of treatments
    • 3.2.2.2 Regulatory and reimbursement challenges
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Competitive analysis of major market players
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 First-line treatment
  • 5.2.1 Intravenous immunoglobulin (IVIG)
  • 5.2.2 Plasma exchange (Plasmapheresis)
• 5.3 Supportive treatment

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Acute inflammatory demyelinating polyneuropathy (AIDP)
• 6.3 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• 6.4 Miller fisher syndrome (MFS)
• 6.5 Acute motor axonal neuropathy (AMAN)
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Below 20 years
• 8.3 21-40 years
• 8.4 41-59 years
• 8.5 60 and above

Chapter 9 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Clinics
• 9.4 Rehabilitation centers
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Biogen Inc.
• 11.3 Cadila Healthcare Limited
• 11.4 CSL Behring LLC
• 11.5 F.Hoffmann-La Roche Ltd.
• 11.6 GSK plc
• 11.7 Grifols SA
• 11.8 LGM Pharmaceuticals, Inc.
• 11.9 Merck & Co., Inc.
• 11.10 Octapharma AG
• 11.11 Pfizer Inc.
• 11.12 Takeda Pharmaceutical Company Limited